Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 6—June 2022
Research

Economic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014–2016

Sarah A. HookComments to Author , Seonghye Jeon, Sara A. Niesobecki, AmberJean P. Hansen, James I. Meek, Jenna K.H. Bjork, Franny M. Dorr, Heather J. Rutz, Katherine A. Feldman, Jennifer L. White, P. Bryon Backenson, Manjunath B. Shankar, Martin I. Meltzer, and Alison F. Hinckley
Author affiliations: Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (S.A. Hook, A.F. Hinckley); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S. Jeon, M.B. Shankar, M.I. Meltzer); Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut, USA (S.A. Niesobecki, A.P. Hansen, J.I. Meek); Minnesota Department of Health, St. Paul, Minnesota, USA (J.K.H. Bjork, F.M. Dorr); Maryland Department of Health, Baltimore, Maryland, USA (H.J. Rutz, K.A. Feldman); New York State Department of Health, Albany, New York, USA (J.L. White, P.B. Backenson)

Main Article

Table 1

Demographic characteristics of 901 participants in study of economic burden of reported Lyme disease in high-incidence areas, United States, 2014–2016

Characteristic No. participants Unweighted % Weighted %
Disease category*
Confirmed localized 402 44.6 54.5
Confirmed disseminated 238 26.4 21.2
Probable
 261
 29.0
 24.2
Age group, y
<18 259 28.7 28.4
18–45 145 16.1 16.1
46–65 326 36.2 36.1
>65
 171
 19.0
 19.4
Sex
F 385 42.7 43.1
M
 516
 57.3
 56.9
Race
Non-White 59 6.5 6.4
White
 842
 93.5
 93.6
State
Connecticut 225 25.0 23.7
Maryland 239 26.5 26.8
Minnesota 268 29.7 29.6
New York
 169
 18.8
 20.0
Income†
<$60,000 238 29.2 28.8
>$60,000
 576
 70.8
 71.2
Insurance
Private 632 70.1 70.2
Other 269 29.9 29.8

*Disease categories were derived from the surveillance case definition for Lyme disease (24). Those with confirmed Lyme disease were divided into 2 groups: confirmed localized disease (i.e., those with erythema migrans) and confirmed disseminated disease (i.e., those with arthritis, lymphocytic meningitis, cranial neuritis or facial palsy, radiculoneuropathy, encephalomyelitis, or 2nd or 3rd degree heart block). Those classified as probable met the probable case definition, plus had >1 symptom reported by a clinician. †Participants were not required to provide information on income; n = 814.

Main Article

Page created: April 03, 2022
Page updated: May 22, 2022
Page reviewed: May 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external